Standard Biotools Inc (LAB) 13F Filing Data & Analysis (Q2 2026)

Standard BioTools Inc. (ticker: LAB) filed this 8-K on August 5, 2026, to disclose its second-quarter earnings. The company issued a press release covering results for the three and six months ended June 30, 2026, attached as Exhibit 99.1, and incorporated most of it by reference into Item 2.02. The filing also lists Items 7.01 and 9.01, though this excerpt doesn't show the substance of those sections — and the actual financial figures are not included here.

No AI summary for this filing type

Standard BioTools (ticker LAB) entered a termination agreement with Illumina on July 24, 2026, receiving about $30 million in cash in exchange for waiving certain earnout rights and terminating royalty and license agreements. Four days later, on July 28, the company agreed to sell its mass cytometry business to Multiplex Bio for $5 million, but the payment will be in the form of a promissory note (no cash upfront), with potential additional $5 million if Multiplex Bio hits a future sale threshold. Standard BioTools might also need to provide up to $10 million in working capital financing to Multiplex Bio. The deal is contingent on shareholder approval and the company's pending merger with Treeline Biosciences.

Standard BioTools Inc. (ticker: LAB) disclosed on July 22 that it received a Nasdaq notice for failing to meet the minimum $1 bid price requirement for 30 consecutive days. The company now has until January 19, 2027 (180 calendar days) to regain compliance, possibly through a reverse stock split. Its stock continues to trade normally on Nasdaq in the meantime, and the company says it intends to resolve the issue.